{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:56:41Z","timestamp":1761746201230,"version":"build-2065373602"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Non-aldosterone producing-adrenal-adenomas (NAPACAs) and polycystic ovary syndrome (PCOS) are associated with insulin-resistance (IR). Whether the co-existence of the two diseases leads to accentuated adverse metabolic profile remains unknown. Aim of this study is the assessment of cardiometabolic risk factors in women with NAPACAs with and without PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective multicenter study including adult premenopausal women categorized as NAPACA (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200945), PCOS (=20) or NAPACA+PCOS (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924), excluding women with hormonally active adenomas, congenital-adrenal-hyperplasia, diabetes, systemic steroid medication or active malignancy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      NAPACA patients were significantly older than the other two groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). All groups did not differ in blood pressure, HbA1c, fasting plasma glucose (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05) or in body-mass-index (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.06). NAPACA+PCOS patients displayed significantly increased insulin resistance (IR) (GIR:\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05, HOMA:\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05, QUICKI:\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05, MATSUDA-index:\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Cortisol levels upon 1-mg-dexamethasone-suppression-test (DST) did not differ among the groups; DHEA-S (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) and testosterone (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01) were significantly higher in the two groups with PCOS patients. Free-androgen-index positively correlated with IR in NAPACA (GIR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01, HOMA\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05, QUICKI\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) and PCOS (GIR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01, HOMA\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01, QUICKI\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01, MATSUDA\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01), while 1mg-DST positively correlated with IR in NAPACA+PCOS (GIR\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.05, HOMA\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05, QUICKI\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05, MATSUDA\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Younger age, higher IR and lower HDL levels predicted the PCOS presence in NAPACA patients whereas the multivariate analysis revealed age and HDL levels as the most important predictors of this association.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings provide evidence for a distinct metabolic pattern in NAPACA+PCOS patients compared to NAPACA patients. Further prospective studies with larger patient cohorts will be necessary to elucidate this observation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-025-04369-7","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:22:14Z","timestamp":1753896134000},"page":"971-981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic phenotype in non-aldosterone producing adrenal adenomas with co-existent polycystic ovary syndrome: a joint Ens@t project"],"prefix":"10.1007","volume":"90","author":[{"given":"Ariadni","family":"Spyroglou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiota","family":"Konstantakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Minnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros","family":"Papalexis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Angelousi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Vasiliadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otilia","family":"Kimpel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djuro","family":"Macut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Donnarumma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Di Dalmazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manousos","family":"Konstadoulakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Mastorakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Kaltsas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystallenia I.","family":"Alexandraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"4369_CR1","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jcem.84.11.6148","volume":"84","author":"E Diamanti-Kandarakis","year":"1999","unstructured":"E. Diamanti-Kandarakis, C.R. Kouli, A.T. Bergiele, F.A. Filandra, T.C. Tsianateli et al., A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84, 4006\u20134011 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4369_CR2","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","volume":"108","author":"HJ Teede","year":"2023","unstructured":"H.J. Teede, C.T. Tay, J.J.E. Laven, A. Dokras, L.J. Moran et al., Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 108, 2447\u20132469 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4369_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000341846","volume":"40","author":"KI Alexandraki","year":"2013","unstructured":"K.I. Alexandraki, G.A. Kaltsas, Endocrinopathies and other disorders inducing a polycystic ovary syndrome phenotype. Front. Horm. Res. 40, 142\u2013157 (2013).","journal-title":"Front. Horm. Res."},{"key":"4369_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","volume":"91","author":"R Azziz","year":"2009","unstructured":"R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale et al., The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456\u2013488 (2009).","journal-title":"Fertil. Steril."},{"key":"4369_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrendo.2018.24","volume":"14","author":"HF Escobar-Morreale","year":"2018","unstructured":"H.F. Escobar-Morreale, Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat. Rev. Endocrinol. 14, 270\u2013284 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"4369_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1043-2760(96)00125-7","volume":"7","author":"E Diamanti-Kandarakis","year":"1996","unstructured":"E. Diamanti-Kandarakis, A. Dunaif, New perspectives in polycystic ovary syndrome. Trends Endocrinol. Metab. 7, 267\u2013271 (1996).","journal-title":"Trends Endocrinol. Metab."},{"key":"4369_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1530\/eje.1.01910","volume":"152","author":"E Diamanti-Kandarakis","year":"2005","unstructured":"E. Diamanti-Kandarakis, K. Alexandraki, A. Protogerou, C. Piperi, C. Papamichael et al., Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur. J. Endocrinol. 152, 749\u2013756 (2005).","journal-title":"Eur. J. Endocrinol."},{"key":"4369_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.14310\/horm.2002.11176","volume":"5","author":"K Alexandraki","year":"2006","unstructured":"K. Alexandraki, A.D. Protogerou, T.G. Papaioannou, C. Piperi, G. Mastorakos et al., Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. Hormones 5, 126\u2013136 (2006).","journal-title":"Hormones"},{"key":"4369_CR9","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3390\/medicina60101656","volume":"60","author":"S Pililis","year":"2024","unstructured":"S. Pililis, S. Lampsas, A. Kountouri, L. Pliouta, E. Korakas et al., The cardiometabolic risk in women with polycystic ovarian syndrome (PCOS): from pathophysiology to diagnosis and treatment. Medicina 60, 1656 (2024).","journal-title":"Medicina"},{"issue":"6","key":"4369_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1210\/er.2011-1034","volume":"33","author":"E Diamanti-Kandarakis","year":"2012","unstructured":"E. Diamanti-Kandarakis, A. Dunaif, Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 33(6), 981\u20131030 (2012).","journal-title":"Endocr. Rev."},{"key":"4369_CR11","first-page":"637","volume":"85","author":"F Mantero","year":"2000","unstructured":"F. Mantero, M. Terzolo, G. Arnaldi, G. Osella, A.M. Masini et al., A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J. Clin. Endocrinol. Metab. 85, 637\u2013644 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4369_CR12","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0467","volume":"175","author":"M Fassnacht","year":"2016","unstructured":"M. Fassnacht, W. Arlt, I. Bancos, H. Dralle, J. Newell-Price et al., Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 175, G1\u2013G34 (2016).","journal-title":"Eur. J. Endocrinol."},{"key":"4369_CR13","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1007\/s00330-019-06202-y","volume":"29","author":"M Taya","year":"2019","unstructured":"M. Taya, V. Paroder, E. Bellin, L.B. Haramati, The relationship between adrenal incidentalomas and mortality risk. Eur. Radiol. 29, 6245\u20136255 (2019).","journal-title":"Eur. Radiol."},{"key":"4369_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S2213-8587(22)00100-0","volume":"10","author":"T Deutschbein","year":"2022","unstructured":"T. Deutschbein, G. Reimondo, G. Di Dalmazi, I. Bancos, J. Patrova et al., Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes Endocrinol. 10, 499\u2013508 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4369_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1210\/jcem.87.3.8277","volume":"87","author":"M Terzolo","year":"2002","unstructured":"M. Terzolo, A. Pia, A. Ali, G. Osella, G. Reimondo et al., Adrenal incidentaloma: a new cause of the metabolic syndrome?. J. Clin. Endocrinol. Metab. 87, 998\u20131003 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4369_CR16","doi-asserted-by":"publisher","first-page":"e77326","DOI":"10.1371\/journal.pone.0077326","volume":"8","author":"CH Anderwald","year":"2013","unstructured":"C.H. Anderwald, A. Tura, A. Gessl, A. Luger, G. Pacini et al., Adequately adapted insulin secretion and decreased hepatic insulin extraction cause elevated insulin concentrations in insulin resistant non-diabetic adrenal incidentaloma patients. PLoS ONE 8, e77326 (2013).","journal-title":"PLoS ONE"},{"key":"4369_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/07435809609043773","volume":"22","author":"M Reincke","year":"1996","unstructured":"M. Reincke, M. Fassnacht, S. Vath, P. Mora, B. Allolio, Adrenal incidentalomas: a manifestation of the metabolic syndrome?. Endocr. Res. 22, 757\u2013761 (1996).","journal-title":"Endocr. Res."},{"key":"4369_CR18","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"E Giovannucci","year":"2010","unstructured":"E. Giovannucci, D.M. Harlan, M.C. Archer, R.M. Bergenstal, S.M. Gapstur et al., Diabetes and cancer: a consensus report. Diabetes Care 33, 1674\u20131685 (2010).","journal-title":"Diabetes Care"},{"key":"4369_CR19","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/ijc.29950","volume":"138","author":"B Altieri","year":"2016","unstructured":"B. Altieri, G. Tirabassi, S. Della Casa, C.L. Ronchi, G. Balercia et al., Adrenocortical tumors and insulin resistance: What is the first step?. Int. J. Cancer 138, 2785\u20132794 (2016).","journal-title":"Int. J. Cancer"},{"key":"4369_CR20","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1210\/en.2016-1804","volume":"158","author":"G Muscogiuri","year":"2017","unstructured":"G. Muscogiuri, M.C. De Martino, M. Negri, C. Pivonello, C. Simeoli et al., Adrenal mass: insight into pathogenesis and a common link with insulin resistance. Endocrinology 158, 1527\u20131532 (2017).","journal-title":"Endocrinology"},{"key":"4369_CR21","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","volume":"189","author":"M Fassnacht","year":"2023","unstructured":"M. Fassnacht, S. Tsagarakis, M. Terzolo, A. Tabarin, A. Sahdev et al., European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 189, G1\u2013G42 (2023).","journal-title":"Eur. J. Endocrinol."},{"key":"4369_CR22","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0015-0282(16)41415-9","volume":"26","author":"AF Clark","year":"1975","unstructured":"A.F. Clark, S. Marcellus, B. deLory, C.E. Bird, Plasma testosterone free index: a better indicator of plasma androgen activity?. Fertil. Steril. 26, 1001\u20131005 (1975).","journal-title":"Fertil. Steril."},{"key":"4369_CR23","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1172\/JCI112886","volume":"79","author":"RN Bergman","year":"1987","unstructured":"R.N. Bergman, R. Prager, A. Volund, J.M. Olefsky, Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J. Clin. Invest. 79, 790\u2013800 (1987).","journal-title":"J. Clin. Invest."},{"key":"4369_CR24","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","volume":"85","author":"A Katz","year":"2000","unstructured":"A. Katz, S.S. Nambi, K. Mather, A.D. Baron, D.A. Follmann et al., Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85, 2402\u20132410 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4369_CR25","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462\u20131470 (1999).","journal-title":"Diabetes Care"},{"key":"4369_CR26","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.4158\/EP-2020-0182","volume":"26","author":"JH Kim","year":"2020","unstructured":"J.H. Kim, M.J. Kim, J.H. Lee, J.W. Yoon, C.S. Shin, Nonfunctioning adrenal incidentalomas are not clinically silent: a longitudinal cohort study. Endocr. Pract. 26, 1406\u20131415 (2020).","journal-title":"Endocr. Pract."},{"key":"4369_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1530\/EJE-08-0707","volume":"160","author":"M Sereg","year":"2009","unstructured":"M. Sereg, A. Szappanos, J. Toke, K. Karlinger, K. Feldman et al., Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur. J. Endocrinol. 160, 647\u2013655 (2009).","journal-title":"Eur. J. Endocrinol."},{"key":"4369_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1530\/eje.0.1480213","volume":"148","author":"G Bernini","year":"2003","unstructured":"G. Bernini, A. Moretti, P. Iacconi, P. Miccoli, R. Nami et al., Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur. J. Endocrinol. 148, 213\u2013219 (2003).","journal-title":"Eur. J. Endocrinol."},{"key":"4369_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2021.100123","volume":"12","author":"L Barrea","year":"2021","unstructured":"L. Barrea, E. Frias-Toral, L. Verde, F. Ceriani, G. Cucalon et al., PCOS and nutritional approaches: differences between lean and obese phenotype. Metab. Open. 12, 100123 (2021).","journal-title":"Metab. Open."},{"key":"4369_CR30","first-page":"263","volume":"14","author":"P Layegh","year":"2016","unstructured":"P. Layegh, Z. Mousavi, D. Farrokh Tehrani, S.M. Parizadeh, M. Khajedaluee, Insulin resistance and endocrine-metabolic abnormalities in polycystic ovarian syndrome: Comparison between obese and non-obese PCOS patients. Int. J. Reprod. Biomed. 14, 263\u2013270 (2016).","journal-title":"Int. J. Reprod. Biomed."},{"key":"4369_CR31","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.metabol.2010.01.007","volume":"59","author":"M Peppa","year":"2010","unstructured":"M. Peppa, E. Boutati, C. Koliaki, N. Papaefstathiou, E. Garoflos et al., Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: a cause-effect relationship?. Metabolism 59, 1435\u20131441 (2010).","journal-title":"Metabolism"},{"key":"4369_CR32","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/cen.13294","volume":"86","author":"L Papanastasiou","year":"2017","unstructured":"L. Papanastasiou, K.I. Alexandraki, I.I. Androulakis, S. Fountoulakis, T. Kounadi et al., Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up. Clin. Endocrinol. 86, 488\u2013498 (2017).","journal-title":"Clin. Endocrinol."},{"key":"4369_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.fertnstert.2011.11.036","volume":"97","author":"JC Marshall","year":"2012","unstructured":"J.C. Marshall, A. Dunaif, Should all women with PCOS be treated for insulin resistance?. Fertil. Steril. 97, 18\u201322 (2012).","journal-title":"Fertil. Steril."},{"key":"4369_CR34","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1210\/jcem.83.8.5041","volume":"83","author":"E Diamanti-Kandarakis","year":"1998","unstructured":"E. Diamanti-Kandarakis, A. Mitrakou, S. Raptis, G. Tolis, A.J. Duleba, The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83, 2699\u20132705 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4369_CR35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1365-2265.2010.03928.x","volume":"74","author":"G Muscogiuri","year":"2011","unstructured":"G. Muscogiuri, G.P. Sorice, A. Prioletta, T. Mezza, C. Cipolla et al., The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship?. Clin. Endocrinol. 74, 300\u2013305 (2011).","journal-title":"Clin. Endocrinol."},{"key":"4369_CR36","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1210\/jc.2013-4064","volume":"99","author":"II Androulakis","year":"2014","unstructured":"I.I. Androulakis, G.A. Kaltsas, G.E. Kollias, A.C. Markou, A.K. Gouli et al., Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J. Clin. Endocrinol. Metab. 99, 2754\u20132762 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4369_CR37","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1046\/j.1365-2265.2000.01006.x","volume":"52","author":"F Beuschlein","year":"2000","unstructured":"F. Beuschlein, M. Borgemeister, J. Schirra, B. Goke, M. Fassnacht et al., Oral glucose tolerance testing but not intravenous glucose administration uncovers hyper-responsiveness of hypothalamo-pituitary-adrenal axis in patients with adrenal incidentalomas. Clin. Endocrinol. 52, 617\u2013623 (2000).","journal-title":"Clin. Endocrinol."},{"key":"4369_CR38","first-page":"952","volume":"81","author":"P Moghetti","year":"1996","unstructured":"P. Moghetti, F. Tosi, R. Castello, C.M. Magnani, C. Negri et al., The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J. Clin. Endocrinol. Metab. 81, 952\u2013960 (1996).","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04369-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:05:45Z","timestamp":1761735945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04369-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4369"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04369-7","relation":{},"ISSN":["1559-0100"],"issn-type":[{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was conducted as part of the European Network for the Study of Adrenal Tumors (ENS@T). The study was conducted according to the Declaration of Helsinki Guidelines and was approved by the Ethics Committee of the Aretaieio Hospital, National and Kapodistrian University of Athens, as coordinating center (Decision Nr. 363\/13-10-2021), and from the respective Ethics Committee of all other participating centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}